Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

Inclusion Criteria: * Arm A: Newly Diagnosed High Grade Glioma Tumor * Arm B: Recurrent, resectable High Grade Glioma or Ependymoma * Stable Neurologic Status * Lanksy/Karnofsky score greater than or equal to 50. * Adequate Bone Marrow Function (ANC≥ 1000/μL, platelets≥ 100,000/μL transfusion independent, Hemoglobin ≥ 8.0 gm/dL with or without transfusion support) * Adequate Liver Function (Bilirubin ≤ 2x institutional normal for age, Alanine transaminase (ALT) ≤ 5x institutional normal for age, Aspartate Aminotransferase (AST) ≤ 5x institutional normal for age) * Adequate Renal Function (Normal creatinine for age and/or glomerular filtration rate ≥ 70 mls/min/1.73 m2) * Female patients of childbearing potential must have a negative serum or urine pregnancy test Exclusion Criteria: * Patients with unresectable disease are not eligible. * Patients with primary spinal cord tumors are not eligible. * Patients with metastatic disease are not eligible for Arm A (this does NOT apply to Arm B). * Patients with a known allergy to any component of the vaccine or any compounds of similar chemical or biologic composition of the vaccine are not eligible. * Patients with known auto-immune disease are excluded. * Patients with known immunodeficiency are excluded. * Patients with a concurrent malignancy are excluded. * Clinically Significant Concurrent Illness * Patients receiving any other anticancer or investigational drug * Patients with uncontrolled seizure disorders * Patients whose…